ABSTRACT
The molecular forms of the N-terminal fragment (hNT) of proopiomelanocortin were studied in cerebrospinal fluid (CSF) from normal subjects, methadone-addicted patients, patients with hydrocephalus, and a patient with Nelson's syndrome. The peptides were characterized by molecular sieving and Concanavalin A-Sepharose chromatography. Immunoreactivity was detected using antibodies directed against the N- and C-terminal portions of the hNT (hNT and gamma 3MSH antibodies, respectively). The mean immunoreactive hNT (IR-hNT) levels in samples of CSF from normal subjects, patients with hydrocephalus, methadone addicts, and the patient with Nelson's syndrome were 410 +/- 158 (+/- SE), 435 +/- 137, 328 +/- 183, and 85,700 pg/mL, respectively. Molecular sieving chromatography revealed one predominant species of IR-hNT and/or gamma 3MSH which coeluted with the authentic hNT-(1-76) marker. However, 10-16% of the total immunoreactivity eluted close to the void volume. No significant differences in the elution profiles were found among these groups. Most (61-69%) of the IR-hNT bound to Concanavalin A, and the elution patterns of samples from this column were similar to that of purified hNT-(1-76). These results support the view that the major molecular form of hNT in CSF is NT-(1-76) as it is in the pituitary gland.
Subject(s)
Peptide Fragments/cerebrospinal fluid , Pro-Opiomelanocortin/cerebrospinal fluid , Adolescent , Adult , Chromatography, Affinity , Chromatography, Gel , Female , Humans , Hydrocephalus/cerebrospinal fluid , Male , Methadone , Middle Aged , Nelson Syndrome/cerebrospinal fluid , Opioid-Related Disorders/cerebrospinal fluid , RadioimmunoassayABSTRACT
Corticotropin-releasing hormone (CRH) levels in the human plasma and cerebrospinal fluid (CSF), and those in the rat hypothalamus, peripheral and hypophyseal portal plasma were studied by a specific h/r CRH RIA and an immunoaffinity procedure. CRH levels in the plasma and CSF were low in patients with hypercortisolemia and those with hypothalamic hypopituitarism, but high in patients with hypocortisolemia except for patients with hypothalamic hypopituitarism. Plasma CRH responded to insulin-induced hypoglycemia (ITT) those with Addison's disease and those with primary hypopituitarism, but not in patients with Cushing's syndrome or in patients with hypothalamic hypopituitarism. The results suggest that the major component of plasma CRH may be of hypothalamic origin, but other extrahypothalamic tissues cannot be ruled out as minor sources of plasma CRH. In addition, the measurement of CRH levels in the plasma and CSF seems to be of value in evaluating the hypothalamic function. The short negative feedback mechanism regulating CRH release was demonstrated in humans and rats. In the absence of the long negative feedback control of ACTH secretion by glucocorticoids, ACTH originating from the pituitary may regulate ACTH secretion form the pituitary through inhibition of CRH release.
Subject(s)
Corticotropin-Releasing Hormone/analysis , Addison Disease/blood , Addison Disease/cerebrospinal fluid , Addison Disease/metabolism , Animals , Corticotropin-Releasing Hormone/blood , Corticotropin-Releasing Hormone/cerebrospinal fluid , Cushing Syndrome/blood , Cushing Syndrome/cerebrospinal fluid , Cushing Syndrome/metabolism , Humans , Hypopituitarism/blood , Hypopituitarism/cerebrospinal fluid , Hypopituitarism/metabolism , Hypothalamus/analysis , Hypothalamus/metabolism , Immunoassay , Nelson Syndrome/blood , Nelson Syndrome/cerebrospinal fluid , Nelson Syndrome/metabolism , Pituitary Gland/analysis , Pituitary Gland/metabolism , Radioimmunoassay , Rats , Reference Values , Tissue DistributionABSTRACT
The concentrations of immunoreactive corticotropin-releasing factor (I-CRF) in human cerebrospinal fluid (CSF) were measured utilizing immunoaffinity chromatography and RIA in patients with no endocrine disease, patients with Cushing's disease, Nelson's syndrome, Sheehan's syndrome, Addison's disease and steroid treated patients. On high performance liquid chromatography, the elution profile and retention time of I-CRF in CSF were not identical with ovine CRF. I-CRF concentrations in CSF from patients with Cushing's disease and Sheehan's syndrome were lower than those from normal subjects, however those from patients with Nelson's syndrome and Addison's disease were within the normal range. I-CRF concentrations in CSF from patients with Cushing's disease returned to normal levels 2-9 months after pituitary adenomectomy. These results suggest that CSF I-CRF concentrations are reduced by increased plasma corticosteroid levels.
Subject(s)
Adrenal Gland Diseases/cerebrospinal fluid , Corticotropin-Releasing Hormone/cerebrospinal fluid , Pituitary Diseases/cerebrospinal fluid , Addison Disease/cerebrospinal fluid , Adrenal Cortex Hormones/therapeutic use , Cushing Syndrome/cerebrospinal fluid , Cushing Syndrome/surgery , Endocrine System Diseases/drug therapy , Female , Humans , Hypopituitarism/cerebrospinal fluid , Kinetics , Male , Nelson Syndrome/cerebrospinal fluidABSTRACT
Cerebrospinal fluid polyamine determinations were performed in 21 patients harboring pituitary tumors and six patients with nonneoplastic pituitary disease. Although CSF putrescine levels were significantly elevated in some patients harboring tumors, other patients showed no elevation. Polyamine levels did not correlate with tumor size, as assessed by the presence or absence of suprasellar extension. Data on patients harboring nonneoplastic pituitary disease were variable. Compared with other findings from this laboratory on the use of polyamine levels for the diagnosis and management of other brain tumors, these findings suggest that CSF polyamine levels will not have a significant diagnostic role in the treatment of patients suspected to have pituitary disease.
